Clinical Trials Directory

Trials / Conditions / RAS Mutation

RAS Mutation

17 registered clinical trials studyying RAS Mutation — 11 currently recruiting.

StatusTrialSponsorPhase
RecruitingEvaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS M
NCT07252479
Adlai Nortye Biopharma Co., Ltd.Phase 1
RecruitingStudy to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
NCT06922591
Tango Therapeutics, Inc.Phase 1 / Phase 2
TerminatedStudy of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (M
NCT06287463
Deciphera Pharmaceuticals, LLCPhase 1
RecruitingICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC
NCT06321081
Beijing HospitalPhase 2
RecruitingPAS-004 in Patients With Advanced Solid Tumors
NCT06299839
Pasithea Therapeutics Corp.Phase 1
RecruitingCadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unrese
NCT06218810
Fudan UniversityPhase 2
RecruitingLeflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
NCT06229340
N.N. Petrov National Medical Research Center of OncologyPhase 2
TerminatedSafety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
NCT05831995
ABM Therapeutics CorporationPhase 1
CompletedNAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NR
NCT05340621
OnKure, Inc.Phase 1 / Phase 2
TerminatedTovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
NCT07121829
Day One Biopharmaceuticals, Inc.Phase 1
UnknownCentralized Tumour Board and Secondary Intervention Rate in mCRC
NCT04852250
Ludwig-Maximilians - University of Munich—
RecruitingPD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC
NCT06206096
Chinese PLA General HospitalPhase 2
RecruitingStudy in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or B
NCT04776655
Azienda USL Reggio Emilia - IRCCSPhase 3
RecruitingA Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT04678648
RasCal Therapeutics, Inc.Phase 1
UnknownSintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer
NCT04194359
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityPhase 2
RecruitingHematological Anomalies in Children With Rasopathy
NCT04286360
Assistance Publique - Hôpitaux de Paris—
RecruitingRASopathy Biorepository
NCT04395495
Children's Hospital Medical Center, Cincinnati—